Obetrol

Last updated
Obetrol
Obetrol-resized.jpg
Combination of
Dextroamphetamine Psychostimulant
Amphetamine Psychostimulant
Methamphetamine Psychostimulant
Clinical data
Routes of
administration
Oral
Legal status
Legal status
Identifiers
ChemSpider
  • none
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Obetrol was the brand name of a drug combining several amphetamine salts indicated for the treatment of exogenous obesity. It was originally sold by the American company Obetrol Pharmaceuticals. Obetrol was a popular diet pill in America in the 1950s and 1960s. [1]

Contents

The original formulation of amphetamine mixed salts that included methamphetamine was approved by the U.S. Food and Drug Administration (FDA) on January 19, 1960, under the name Obetrol. [2] Indicated for exogenous obesity, [3] between 1965 and 1973, Obetrol was marketed in 10 mg and 20 mg strength through Obetrol Pharmaceuticals division of the American pharmaceutical company Rexar. When sold directly to physicians, Obetrol used the brand name Oby-Rex. [4]

Formulations

Original

In the 1950s, Obetrol was manufactured by Obetrol Pharmaceuticals, in Brooklyn, New York. The company later became a division of Rexar Pharmacal Corporation, which was also headquartered in Brooklyn. Sometime prior to 1972, Rexar Pharmacal moved its manufacturing facilities, including its Obetrol Pharmaceutical Division, to Valley Stream, New York. By the 1990s, Obetrol Pharmaceuticals had been wholly absorbed by Rexar Pharmacal and was no longer noted as a division of Rexar. In 1993, Rexar was acquired by Richwood Pharmaceuticals of Florence, Kentucky, which in 1995 merged with Shire Pharmaceuticals.[ citation needed ]

The 1972 edition of the Physicians' Desk Reference lists Obetrol containing (10 mg tablet):

Obetrol was also available in 20 mg tablets which contained twice the quantity of its ingredients, in the same proportions. The 10 mg tablets were blue, and the 20 mg were orange. Both were inscribed with the letters, "OP".[ citation needed ]

In 1970 the FDA issued an order requiring new drug applications for previously approved amphetamine products. [5] The FDA was critical of combinations of amphetamines and non-amphetamines, but also considered amphetamine and methamphetamine mixtures a combination drug, and required the ingredients to be effective and safe individually and in combination. [6] In September 1973 the FDA withdrew approval for Obetrol under the FDA Drug Efficacy Study Implementation program. [7] [5] The FDA cited the research submitted was vague, subjective, lacking controls or poorly controlled, incomplete, did not test individual ingredients, and had other deficiencies. [5]

Modified

Because FDA considered combinations of amphetamine and dextroamphetamine salt a single entity, [6] Rexar simply reformulated Obetrol to exclude methamphetamine salts and continued to sell this new formulation under the same Obetrol brand name. This new unapproved formulation was later rebranded and sold as Adderall by Richwood after it acquired Rexar resulting in FDA warning in 1994. Richwood resubmitted this formulation as NDA 11-522 and Adderall gained FDA approval for the treatment of attention-deficit/hyperactivity disorder on February 13, 1996. [7]

The reformulated Obetrol (and Adderall) contained equal portions of:

These tablets were also blue and orange, but were inscribed with the letters, "OB".[ citation needed ]

When Richwood acquired Rexar, the drug's name was changed from Obetrol to Adderall, and the drug was marketed for use in the treatment of Attention Deficit Disorder (in both children and adults). The old Rexar facility underwent extensive renovations and improvements, and continued to manufacture the drug for several years. During these years, the drug Adderall was identical to the most recent formulation of Obetrol, except that the inscription on the pills was changed to "AD".[ citation needed ]

Sometime after 2000, Shire closed the Rexar manufacturing facility, discontinued immediate-release Adderall and outsourced Adderall XR (extended-release) to a manufacturer in North Carolina. Other companies had begun manufacturing generic versions of Adderall, and the trade name was eventually sold to Barr Pharmaceuticals (acquired by Teva in 2008).[ citation needed ]

There is no drug commercially marketed called Obetrol at this time, nor has there been since Richwood acquired Rexar Pharmacal.[ citation needed ]

Abuse

The ready availability of methamphetamine-based medications in the 1960s led to their use and abuse as recreational drugs. Obetrol was the recreational drug of choice for artist Andy Warhol. [8] Obetrol was abused by a character named Chris Fogle in David Foster Wallace's novel The Pale King . [9] "Obetrolling" or "doubling" were the terms used by the character to refer to getting wired on Obetrol, which increased his self-awareness and made him feel alive. [9] :180

Related Research Articles

<span class="mw-page-title-main">Amphetamine</span> Central nervous system stimulant

Amphetamine is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. Amphetamine was discovered as a chemical in 1887 by Lazăr Edeleanu, and then as a drug in the late 1920s. It exists as two enantiomers: levoamphetamine and dextroamphetamine. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers in their pure amine forms. The term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. It is a prescription drug in many countries, and unauthorized possession and distribution of amphetamine are often tightly controlled due to the significant health risks associated with recreational use.

<span class="mw-page-title-main">Stimulant</span> Drug that increases activity of central nervous system

Stimulants are a class of drugs that increase the activity of the brain and the spinal cord. They are used for various purposes, such as enhancing alertness, attention, motivation, cognition, mood, and physical performance. Some of the most common stimulants are caffeine, nicotine, amphetamines, cocaine, and modafinil.

<span class="mw-page-title-main">Pseudoephedrine</span> Pharmaceutical drug

Pseudoephedrine (PSE) is a sympathomimetic drug of the phenethylamine and amphetamine chemical classes. It may be used as a nasal/sinus decongestant, as a stimulant, or as a wakefulness-promoting agent in higher doses.

In chemistry, a racemic mixture or racemate, is one that has equal amounts of left- and right-handed enantiomers of a chiral molecule or salt. Racemic mixtures are rare in nature, but many compounds are produced industrially as racemates.

<span class="mw-page-title-main">Over-the-counter drug</span> Medication available without a prescription

Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription. In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician's care. OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) rather than final products. By regulating APIs instead of specific drug formulations, governments allow manufacturers the freedom to formulate ingredients, or combinations of ingredients, into proprietary mixtures.

<span class="mw-page-title-main">Dextroamphetamine</span> CNS stimulant and isomer of amphetamine

Dextroamphetamine is a potent central nervous system (CNS) stimulant and enantiomer of amphetamine that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used as an athletic performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant.

Oxycodone/aspirin is a combination drug marketed by Endo Pharmaceuticals. It is a tablet containing a mixture of 325 mg of aspirin and 4.8355 mg of oxycodone HCl ; it is an opioid/non-opioid combination used to treat moderate to moderately severe pain. The safety of the combination during pregnancy has not been established, although aspirin is generally contraindicated during pregnancy, and the drug has been placed in pregnancy category D. Inactive ingredients include D&C Yellow 10, FD&C Yellow 6, microcrystalline cellulose, and corn starch. Percodan was first marketed by DuPont Pharmaceuticals and prescribed in the United States in 1950. Once a widely prescribed painkiller, it has largely been replaced by alternative oxycodone compounds containing paracetamol (acetaminophen) instead of aspirin, such as Percocet.

An anorectic or anorexic is a drug which reduces appetite, resulting in lower food consumption, leading to weight loss. These substances work by affecting the central nervous system or certain neurotransmitters to create a feeling of fullness or reduce the desire to eat. The understanding of anorexiant effects is crucial in the development of interventions for weight management, eating disorders, and related health concerns. The anorexiant effect can be induced through diverse mechanisms, ranging from hormonal regulation to neural signaling. Ghrelin, leptin, and peptide YY are among the hormones involved in appetite control. Additionally, neurotransmitters such as serotonin and dopamine in the central nervous system contribute significantly to the regulation of food intake.

<span class="mw-page-title-main">Adderall</span> Drug mixture used mainly to treat ADHD and narcolepsy

Adderall and Mydayis are trade names for a combination drug called mixed amphetamine salts containing four salts of amphetamine. The mixture is composed of equal parts racemic amphetamine and dextroamphetamine, which produces a (3:1) ratio between dextroamphetamine and levoamphetamine, the two enantiomers of amphetamine. Both enantiomers are stimulants, but differ enough to give Adderall an effects profile distinct from those of racemic amphetamine or dextroamphetamine, which are marketed as Evekeo and Dexedrine/Zenzedi, respectively. Adderall is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used illicitly as an athletic performance enhancer, cognitive enhancer, appetite suppressant, and recreationally as a euphoriant. It is a central nervous system (CNS) stimulant of the phenethylamine class.

<span class="mw-page-title-main">Oxymorphone</span> Opioid analgesic drug

Oxymorphone is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.

<span class="mw-page-title-main">Dextropropoxyphene</span> Withdrawn opioid medication

Dextropropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. It is an optical isomer of levopropoxyphene. It is intended to treat mild pain and also has antitussive and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. It is still available in Australia, albeit with restrictions after an application by its manufacturer to review its proposed banning. Its onset of analgesia is said to be 20–30 minutes and peak effects are seen about 1.5–2.0 hours after oral administration.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Dexamyl was a brand name combination drug composed of sodium amobarbital and dextroamphetamine sulfate (Dexedrine) within the same pill. It was widely abused, and is no longer manufactured.

A combination drug or a fixed-dose combination (FDC) is a medicine that includes two or more active ingredients combined in a single dosage form. Terms like "combination drug" or "combination drug product" can be common shorthand for an FDC product, although the latter is more precise if in fact referring to a mass-produced product having a predetermined combination of drugs and respective dosages. And it should also be distinguished from the term "combination product" in medical contexts, which without further specification can refer to products that combine different types of medical products—such as device/drug combinations as opposed to drug/drug combinations. When a combination drug product is a "pill", then it may also be a kind of "polypill" or combopill.

<span class="mw-page-title-main">Lisdexamfetamine</span> Central nervous system stimulant prodrug

Lisdexamfetamine, most commonly sold under the brand name Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults, and for moderate-to-severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours and last for up to 14 hours. In the United Kingdom, it is usually less preferred to methylphenidate for the treatment of children.

Eskatrol was an amphetamine weight loss agent which was removed by the U.S. Food and Drug Administration (FDA) in 1981 after its manufacturer, SmithKline & French (SKF), failed to prove the therapeutic effectiveness (Emax) of the medication. At the time it was among the 200 most widely prescribed drugs in the United States. Others included Dexamyl and Desbutal pills. Eskatrol contained dextroamphetamine sulfate (Dexedrine) and prochlorperazine (Compazine), a typical antipsychotic.

Donnatal is a combination medication that provides natural belladonna alkaloids in a specific fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation. Donnatal is manufactured for Concordia Pharmaceuticals by IriSys, LLC. It is available as tablets and 5 mL elixir. Active ingredients are listed as: phenobarbital (16.2 mg), hyoscyamine sulfate (0.1037 mg), atropine sulfate (0.0194 mg), and scopolamine hydrobromide (0.0065 mg). The latter two ingredients are found in plants of the family Solanaceae, such as belladonna.

<span class="mw-page-title-main">Levoamphetamine</span> CNS stimulant and isomer of amphetamine

Levoamphetamine is a central nervous system (CNS) stimulant known to increase wakefulness and concentration in association with decreased appetite and fatigue. Pharmaceuticals that contain levoamphetamine are currently indicated and prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy in some countries.

Desbutal was a brand name drug by Abbott containing 5 mg methamphetamine hydrochloride (Desoxyn) and 30 mg pentobarbital sodium (Nembutal); a substituted amphetamine and a barbiturate combined within the same pill. Desbutal was marketed as an antidepressant as well as a medication for the treatment of obesity, narcolepsy, parkinsonism, and alcoholism, although it was commonly also prescribed off-label for miscellaneous ailments. It had a high abuse potential and is no longer manufactured.

Amphetamine and methamphetamine are central nervous system stimulants used to treat a variety of conditions. When used recreationally, they are colloquially known as "speed" or sometimes "crank". Amphetamine was first synthesized in 1887 in Germany by Romanian chemist Lazăr Edeleanu, who named it phenylisopropylamine. Around the same time, Japanese organic chemist Nagai Nagayoshi isolated ephedrine from the Chinese ephedra plant and later developed a method for ephedrine synthesis. Methamphetamine was synthesized from ephedrine in 1893 by Nagayoshi. Neither drug had a pharmacological use until 1934, when Smith, Kline & French began selling amphetamine as an inhaler under the trade name Benzedrine for congestion.

References

  1. Rasmussen N (2008). "A bromide for the Go-Go Years". On speed : the many lives of amphetamine. New York: New York University Press. p. 148, fig.33. ISBN   9780814776278. Archived from the original on 2021-03-02. Retrieved 2016-11-06.
  2. "Adverse events reported with immediate-release mixed amphetamine salt products" (PDF). Center for Drug Evaluation and Research (CDER) – United States Food and Drug Administration (FDA). 2006-02-01. Archived (PDF) from the original on 2011-08-19. Retrieved 2013-05-20.
  3. Physicians' Desk Reference (20 ed.). Medical Economics. 1966. p. 811.; Physicians' Desk Reference (25 ed.). Medical Economics. 1973. p. 1027.
  4. United States. Congress. Senate. Select Committee on Small Business. Committee on Monopoly (1975). Competitive Problems in the Drug Industry. Vol. 28. U.S. Government Printing Office. p. 13586. Archived from the original on 2022-07-30. Retrieved 2022-07-05. 'Obetrol' was the trade name when the drug was sold to wholesalers, while 'Oby-Rex' was the trade name used when the same drug was sold to doctors.{{cite book}}: |last= has generic name (help)
  5. 1 2 3 38 FR 26748
  6. 1 2 38 FR 4279
  7. 1 2 "REGULATORY NEWS: Richwood's Adderall". Health News Daily. 22 February 1996. Archived from the original on 23 May 2016. Retrieved 29 May 2013.
  8. Bockris V (1990). Warhol. Penguin.
  9. 1 2 Wallace DF (2011). "Chapter 22 or subsection 22". The Pale King. Penguin Adult. ISBN   978-0-241-14480-0.